|
|
Article: Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma Fractionation Technology from ProMetic Life Sciences.
- Article from:
- PR Newswire
- Article date:
- August 29, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Technology Expected to Give Company's Hyperimmune Product Candidates Key Competitive Advantages: Increased Yield and Better Product Margins --
BOCA RATON, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that it has obtained the exclusive rights to use a novel hyperimmune immunoglobulin extraction technology from ProMetic Life Sciences Inc., a global biopharmaceutical company based in Montreal, Canada, in the manufacture of certain of Nabi Biopharmaceuticals' pipeline hyperimmune products. Access to this technology is expected to provide higher yields of Nabi Biopharmaceuticals' Civacir(R) [Hepatitis C Immune Globulin ...